TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Emmanuel S Antonarakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.